ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1956

68Ga-FAPI-04 and 18F-FDG PET/ CT in MDA5 dermatomyositis-associated interstitial lung disease: a single-center, pilot study

Jia Li1, Weijun Wei2, Lianghua Li2, Wenwen Xu3, Jianjun Liu2 and Shuang Ye4, 1Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic), 2Department of Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200217, China., Shanghai, China (People's Republic), 3Department of Rheumatology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200217, China., Shanghai, China (People's Republic), 4Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, Shanghai, Shanghai, China (People's Republic)

Meeting: ACR Convergence 2025

Keywords: dermatomyositis, Imaging, interstitial lung disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (1936–1971) Imaging of Rheumatic Diseases Poster

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in MDA5 dermatomyositis (MDA5-DM). Fibrosis and inflammation are pivotal drivers in the pathogenesis of DM-ILD. This study aims to investigate the imaging characteristics of ⁶⁸Ga-FAPI-04 and ¹⁸F-FDG PET/CT in MDA5 DM ILD, and to evaluate the association between pulmonary metabolic parameters of fibrosis and inflammation and mortality in MDA5 DM-ILD.

Methods: Between August 2022 and November 2024, 20 patients with newly diagnosed (duration ≤6 months) MDA5 DM were enrolled in the study, followed by a 6-month longitudinal observation period.All participants underwent baseline ⁶⁸Ga-FAPI-04 PET/CT and ¹⁸F-FDG PET/CT scanning. Parameters including total lesion volume (TLV), total target-to-background ratio (TBR_total), mean TBR (TBR_mean), and maximum TBR (TBR_max) based on standardized uptake values (SUV) were quantified.Non-parametric Mann-Whitney U tests compared group differences.Spearman’s rank correlation analyes parameter associations, and point-biserial correlation coefficients quantified associations with mortality.

Results: The study included 20 patients with a mean age of 50.2 ± 13.8 years ,and 60% were male. The median disease duration was 2.0 months (interquartile range [IQR], 1.0–3.0 months). During follow-up , mortality was observed in 3 of the 20 enrolled patients. Lesion volumes quantified by ⁶⁸Ga-FAPI-04 and ¹⁸F-FDG PET/CT exhibited high concordance, with a robust positive correlation (Spearman’s ρ = 0.93), indicating spatial colocalization of inflammation and fibroblast activation in the affected regions. TBRmax FAPI and TBRmean also showed a strong positive correlation (Spearman’s ρ=0.92). Deceased patients demonstrated significantly elevated ¹⁸F-FDG TBRmax values compared to survivors (median: 5.97 vs. 2.04, P=0.04), suggesting that inflammatory activity within lung lesions may contribute to the mortality risk of individuals with MDA5 DM.

Conclusion: In MDA5 DM patients, pulmonary lesions were characterized by hypermetabolism and active fibrosis. The ¹⁸F-FDG TBRmax emerged as a potential prognostic marker for mortality, reflecting localized hypermetabolism in lung tissue that may indicate aggressive disease progression and correlate with poor clinical outcomes. These findings highlight the complementary roles of inflammation (FDG) and fibrosis (FAPI) imaging in characterizing disease severity. Further studies are warranted to validate the prognostic utility of TBRmax FDG and explore integrated imaging strategies for risk stratification in MDA5 DM-associated interstitial lung disease.

Supporting image 1Figure 1 68Ga-FAPI-04 and 18F-FDG PET/CT imaging in a representative patient

Supporting image 2Figure 2 The association between pulmonary metabolic parameters of FAPI and FDG in MDA5 DM-ILD.

Supporting image 3Figure 3 Boxplot of TBRmax for FDG and FAPI Tracers in Different Regions


Disclosures: J. Li: None; W. Wei: None; L. Li: None; W. Xu: None; J. Liu: None; S. Ye: None.

To cite this abstract in AMA style:

Li J, Wei W, Li L, Xu W, Liu J, Ye S. 68Ga-FAPI-04 and 18F-FDG PET/ CT in MDA5 dermatomyositis-associated interstitial lung disease: a single-center, pilot study [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/68ga-fapi-04-and-18f-fdg-pet-ct-in-mda5-dermatomyositis-associated-interstitial-lung-disease-a-single-center-pilot-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/68ga-fapi-04-and-18f-fdg-pet-ct-in-mda5-dermatomyositis-associated-interstitial-lung-disease-a-single-center-pilot-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology